SciTech Development Invited to NYC Oncology Investor Conference November 12-13, 2019

 
 
Spread the Word
Listed Under

Tag:
nanoFenretinide

Industry:
Biotech

Location:
Grosse Pointe - Michigan - US

Subject:
Awards

GROSSE POINTE, Mich. - Oct. 30, 2019 - PRLog -- SciTech Development, a clinical stage drug development company, is pleased to announce that it has been invited to participate in the NYC Oncology Investor Conference 2019 at 1155 6th Ave 22nd Floor, New York, NY. The conference will be held on November 12 and 13 and includes leading life science and oncology venture capitalists, family offices, lawyers, pharma executives, startup public and private cancer companies and cancer foundations for a discussion on trends, opportunities and risks in oncology investing. The conference will feature corporate presentations by a select group of public and private oncology companies, and updates on cutting edge science.

SciTech will be presenting its ST-001 nanoFenretinide technology, which is a small-molecule cancer drug employing a nanoparticle suspension for intravenous administration. ST-001 is comprised of fenretinide in a patented combination with carefully selected non-toxic phospholipids. SciTech's product pipeline includes fenretinide formulations for the treatment of several cancer indications. For ST-001 nanoFenretinide investment and partnering opportunities contact Earle Holsapple | (313) 263-4887 | eth@scitechdevelopment.com

The company has submitted an Investigational New Drug (IND) Application for ST-001 nanoFenretinide and the FDA has granted it Orphan Drug Status for the treatment of two types of non-Hodgkin's lymphoma (NHL): peripheral T-cell lymphoma (PTCL) and cutaneous T-cell lymphoma (CTCL).

Information regarding SciTech's nano formulation technology and oncology drug product ST-001 nanoFenretinide is available from SciTech Development, LLC by calling +1-313-938-5517 or online at https://www.scitechdevelopment.com/

About SciTech Development

SciTech Development, LLC is a clinical stage drug development company currently bringing to market a proven cancer drug for diseases with otherwise limited therapeutic options. SciTech Development is headquartered in the Metropolitan Detroit Michigan Area with laboratories at the Sinai Hospital BioIncubator in Baltimore Maryland.

Contact
SciTech Development LLC
***@scitechdevelopment.com
End
Email:***@scitechdevelopment.com Email Verified
Tags:nanoFenretinide
Industry:Biotech
Location:Grosse Pointe - Michigan - United States
Subject:Awards
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse
SciTech Development LLC PRs
Trending News
Most Viewed
Top Daily News



Like PRLog?
9K2K1K
Click to Share